{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:15:30Z","timestamp":1790129730849,"version":"4.0.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To investigate the effects of different antibiotic regimens used in the treatment of preterm premature rupture of membranes (PPROM) on maternal and fetal outcomes after 34 weeks of gestation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 40 pregnant women diagnosed with PPROM between 34 and 37 weeks of gestation were enrolled in this randomized controlled trial and allocated equally into 2 groups. Group 1 received sulbactam\u2013ampicillin, azithromycin, and amoxicillin, whereas Group-2 received ceftriaxone, clarithromycin, and amoxicillin. The primary outcome was neonatal intensive care unit (NICU) length of stay. Recorded variables included maternal age, gestational age, obstetric history, time of delivery, latency period, infection markers (white blood cell count and C-reactive protein), neonatal birth weight, Apgar scores, NICU admission, mode of delivery, and maternal complications. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 27.0 (Armonk).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      No statistically significant differences were observed between the groups in terms of age, obstetric age, obstetric history, time of delivery, infection markers (white blood cell, C-reactive protein), and type of delivery (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u2005.05). The difference between the groups in terms of NICU requirement and stay duration was not statistically significant; Group 1: mean 8.3\u2005\u00b1\u20056.7 days and Group 2: 4.3\u2005\u00b1\u20051.9 days (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.356). The incidence of maternal complications showed no statistically significant difference; chorioamnionitis was observed in 4 patients (20.0%) in Group 1 and in a patient (5.0%) in Group 2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.141). No difference was observed type of delivery and history of PPROM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The 2 different antibiotic regimens administered to pregnant women diagnosed with PPROM after the 34th week of gestation demonstrated similar clinical effects in terms of maternal and neonatal outcomes. Although the differences in NICU stay duration and the number of chorioamnionitis cases were not statistically significant, we believe that these findings could reach significance in studies with larger sample sizes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047524","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:00:25Z","timestamp":1770404425000},"page":"e47524","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Randomized controlled trial on the effects of different antibiotic regimens in preterm premature rupture of membranes after 34 weeks"],"prefix":"10.1097","volume":"105","author":[{"given":"G\u00fclcan","family":"Karata\u015f Gezen","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Obstetrics and Gynecology, Van Yuzuncu Yil University, Tusba, Van, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4599-1173","authenticated-orcid":false,"given":"Onur","family":"Karaaslan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Obstetrics and Gynecology, Van Yuzuncu Yil University, Tusba, Van, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/AOG.0000000000003700","article-title":"Prelabor rupture of membranes: ACOG practice bulletin, number 217.","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(08)60074-4","article-title":"Epidemiology and causes of preterm birth.","volume":"371","author":"Goldenberg","year":"2008","journal-title":"Lancet"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jogc.2022.08.014","article-title":"Guideline No. 430: diagnosis and management of preterm prelabour rupture of membranes.","volume":"44","author":"Ronzoni","year":"2022","journal-title":"J Obstet Gynaecol Can"},{"key":"R4-20260915","first-page":"CD001058","article-title":"Antibiotics for preterm rupture of membranes.","volume":"2013","author":"Kenyon","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(00)04233-1","article-title":"Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial.","volume":"357","author":"Kenyon","year":"2001","journal-title":"Lancet"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"100978","DOI":"10.1016\/j.ajogmf.2023.100978","article-title":"Efficacy of prophylactic antibiotics for preterm premature rupture of membranes: a systematic review and network meta-analysis.","volume":"5","author":"Lin","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"Suppl 1","key":"R7-20260915","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1471-0528.2005.00582.x","article-title":"Preterm premature rupture of membranes: diagnosis, evaluation and management strategies.","volume":"112","author":"Simhan","year":"2005","journal-title":"BJOG"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"100900","DOI":"10.1016\/j.ajogmf.2023.100900","article-title":"Compared perinatal outcomes of two prophylactic antibiotic regimens for preterm premature rupture of membranes: a randomized controlled trial.","volume":"5","author":"Sgayer","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3109\/14767058.2015.1103729","article-title":"A new antibiotic regimen treats and prevents intra-amniotic inflammation\/infection in patients with preterm PPROM.","volume":"29","author":"Lee","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R10-20260915","first-page":"e92985","article-title":"Neonatal outcome after expectant management of Preterm Premature Rupture of Membranes (PPROM) between 34\u2009+\u20090 and 36\u2009+\u20096 weeks of gestation: a single-center cohort study.","volume":"17","author":"Welp","year":"2025","journal-title":"Cureus"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"101563","DOI":"10.1016\/j.ajogmf.2024.101563","article-title":"PPROM in the late preterm period: an argument for expectant management.","volume":"7","author":"Lee","year":"2025","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/CMR.00031-13","article-title":"Early-onset neonatal sepsis.","volume":"27","author":"Simonsen","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1542\/peds.2010-2217","article-title":"Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues.","volume":"127","author":"Stoll","year":"2011","journal-title":"Pediatrics"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/uog.21884","article-title":"Effect on perinatal outcome of prophylactic antibiotics in preterm prelabor rupture of membranes: network meta-analysis of randomized controlled ftrials.","volume":"55","author":"Chatzakis","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM197306072882307","article-title":"Transplacental passage of erythromycin and clindamycin.","volume":"288","author":"Philipson","year":"1973","journal-title":"N Engl J Med"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1471-0528.2000.tb13339.x","article-title":"The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin.","volume":"107","author":"Heikkinen","year":"2000","journal-title":"BJOG"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mob.2003.141","article-title":"Maternal and transplacental pharmacokinetics of azithromycin.","volume":"188","author":"Ramsey","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1067\/mob.2003.171","article-title":"Placental passage of clarithromycin surpasses other macrolide antibiotics.","volume":"188","author":"Witt","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1515\/jpm-2012-0038","article-title":"Placental transfer of clarithromycin in human pregnancies with preterm premature rupture of membranes.","volume":"40","author":"Park","year":"2012","journal-title":"J Perinat Med"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00003495-199550030-00002","article-title":"Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.","volume":"50","author":"Adu","year":"1995","journal-title":"Drugs"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0025-7125(16)30034-7","article-title":"Third-generation cephalosporins.","volume":"79","author":"Klein","year":"1995","journal-title":"Med Clin North Am"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/00003495-200262070-00005","article-title":"Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.","volume":"62","author":"Lamb","year":"2002","journal-title":"Drugs"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1055\/s-0035-1552935","article-title":"Reconsidering the current preterm premature r\u00fcpt\u00fcre of membranes antibiotic prophylactic protocol.","volume":"32","author":"Wolf","year":"2015","journal-title":"Am J Perinatol"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1186\/s12884-025-08341-1","article-title":"Do we need to reconsider our antibiotic regimen for preterm premature rupture of membranes? Pathogens and perinatal outcome in PPROM.","volume":"25","author":"Schuler","year":"2025","journal-title":"BMC Pregnancy Childbirth"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"2286189","DOI":"10.1080\/14767058.2023.2286189","article-title":"Antibiotic administration reduced intra-amniotic inflammation 7 days after preterm premature rupture of the membranes with intra-amniotic infection.","volume":"36","author":"Ikeda","year":"2023","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jamapediatrics.2013.1199","article-title":"Perinatal infections and neuro-developmental outcome in very preterm and very low-birth-weight infants: a meta-analysis.","volume":"167","author":"Van Vliet","year":"2013","journal-title":"JAMA Pediatr"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3109\/14767058.2015.1020293","article-title":"A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.","volume":"29","author":"Lee","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"e0208302","DOI":"10.1371\/journal.pone.0208302","article-title":"Maternal chorioamnionitis and neurodevelopmental outcomes in preterm and very preterm neonates: a meta-analysis.","volume":"13","author":"Xiao","year":"2018","journal-title":"PLoS One"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamapediatrics.2018.0102","article-title":"Association of histologic chorioamnionitis with perinatal brain injury and early childhood neurodevelopmental outcomes among preterm neonates.","volume":"172","author":"Bierstone","year":"2018","journal-title":"JAMA Pediatr"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/AOG.0b013e3181e90046","article-title":"Chorioamnionitis and cerebral palsy: a meta-analysis.","volume":"116","author":"Shatrov","year":"2010","journal-title":"Obstet Gynecol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:00:42Z","timestamp":1789495242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047524","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"2025-09-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}